tbuckley/cabot-search huggingface dataset:
AB0087 Cytotoxicity and Genotoxicity in Rheumatoid Arthritis: A Dual Effect of Disease and Drugs:
Authors: E. Soliman, M. Tayel, H. Mahrous, S. Shawky
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Studies about cytotoxicity and genotoxicity in rheumatoid arthritis (RA) are limited and the toxicity of Disease Modifying Anti-Rheumatic Drugs (DMARDs) commonly used in treatment is still a concern. <h3>Objectives</h3> to assess cytotoxicity and genotoxicity in RA and the possible cyto and genotoxic effects of some DMARDs used in treatment. <h3>Methods</h3> The study included 30 female RA patients divided according to treatment into three groups and ten healthy controls. Two groups received DMARDs for at least 3 months period: methotrexate (MTX) only group (n=12 patients), MTX with SSZ (sulphasalazine) group (n=8) and ten DMARDs naieve RA who received only Non Steroidal Anti-Inflammatory Drugs (NSAIDs). The MTX dose was 15–20 mg/wk, SSZ dose was 1.5–2 gm daily. All RA on DMARDs received concomitant daily folic acid dose of 0.5 mg.Peripheral blood samples were taken to assess the cytotoxicity by chromosomal analysis (karyotyping) using solid Giemsa stain and GTG-banding according to the International System for Human Chromosome Nomenclature. Genotoxicity and DNA damage was assessed by the miconucleustest usin g cytochalasin –B. <h3>Results</h3> Compared to controls, RA patients had significantly higher chromosomal aberrations (CAs) in the form of breaks, satellite association, endoreduplication, aneuploidy, double minute, and other aberrations. There was also a statistically significant increase in the markers of genotoxicity in RA patients compared to controls: micronuclei (MN), nucleoplasmic bridges (NPB) and necrotic and/or apoptotic cells (Table1). CAs were found in all RA groups, those receiving DMARDs as well as the DMARD naieve group. CAs were significantly higher in MTX and in MTX-SSZ group when compared to RA on NSAIDs only. Meanwhile, there was no significant difference between the CAs in the MTX and the MTX-SSZ groups. In addition, the number of binucleated (BN) cells with MN, NPB, and the necrotic and/or apoptotic cells was statistically higher in MTX-RA and MTX-SSZ-RA compared to the NSAIDs group. Whereas, no statistical difference was found between the two DMARDs groups.RA patients who were on DMARDs for a longer duration (&gt;5 years) showed a statistically significant increase in all cytotoxicity and genotoxicity markers than those for shorter duration (&lt;5 years). <h3>Conclusions</h3> RA patients show significantly increased markers of cytotoxicity and genotoxicity, regardless the type of medications received, sugggesting them to represent underestimated disease features which could provide new insights into its pathogenesis. MTX further aggrevates the cyto- and genotoxicity, whereas SSZ combination does not seem to play additional role and concomitant folic acid supplementation does not provide the sufficient protection. <h3>Disclosure of Interest</h3> None declared
Vital Signs: Disparities in Tobacco-Related Cancer Incidence and Mortality — United States, 2004–2013
Authors: S. Jane Henley, Cheryll C. Thomas, Saida R. Sharapova, Behnoosh Momin, Greta M. Massetti, Deborah M. Winn, Brian S. Armour, Lisa C. Richardson
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

Tobacco use causes at least 12 types of cancer and is the leading preventable cause of cancer.Data from the United States Cancer Statistics dataset for 2004-2013 were used to assess incidence and death rates and trends for cancers that can be caused by tobacco use (tobacco-related cancers: oral cavity and pharynx; esophagus; stomach; colon and rectum; liver; pancreas; larynx; lung, bronchus, and trachea; kidney and renal pelvis; urinary bladder; cervix; and acute myeloid leukemia) by sex, age, race, ethnicity, state, county-level poverty and educational attainment, and cancer site.Each year during 2009-2013, on average, 660,000 persons in the United States received a diagnosis of a tobacco-related cancer, and 343,000 persons died from these cancers. Tobacco-related cancer incidence and death rates were higher among men than women; highest among black men and women; higher in counties with low proportion of college graduates or high level of poverty; lowest in the West; and differed two-fold among states. During 2004-2013, incidence of tobacco-related cancer decreased 1.3% per year and mortality decreased 1.6% per year, with decreases observed across most groups, but not at the same rate.Tobacco-related cancer declined during 2004-2013. However, the burden remains high, and disparities persist among certain groups with higher rates or slower declines in rates.The burden of tobacco-related cancers can be reduced through efforts to prevent and control tobacco use and other comprehensive cancer control efforts focused on reducing cancer risk, detecting cancer early, improving cancer treatments, helping more persons survive cancer, improving cancer survivors' quality of life, and better assisting communities disproportionately impacted by cancer.
Treatment and Clinical Management of Primary Mediastinal Large B-Cell Lymphoma With Sclerosis: MACOP-B Regimen and Mediastinal Radiotherapy Monitored by 67Gallium Scan in 50 Patients
Authors: Pier Luigi Zinzani, Maurizio Martelli, Massimo Magagnoli, Edoardo Pescarmona, Laura Scaramucci, Francesca Palombi, Maurizio Bendandi, Maria Paola Martelli, Stefano Ascani, Giulio Fraternali Orcioni, Stefano A. Pileri, Franco Mandelli, Sante Tura
Journal: Blood (1999)
Diagnosis and relapse: cytogenetically normal acute myelogenous leukemia without FLT3-ITD or MLL-PTD
Authors: W Chien, Q-Y Sun, L-W Ding, A Mayakonda, S Takao, L Liu, S L Lim, K T Tan, M Garg, A De Sousa Maria Varela, J Xiao, N Jacob, K Behrens, C Stocking, M Lill, V Madan, N Hattori, S Gery, S Ogawa, S Wakita, T Ikezoe, L-Y Shih, T Alpermann, T Haferlach, H Yang, H P Koeffler
Journal: Leukemia (2016)
PWE-120 Stricter Adherence to Surveillance Colonoscopy Guidelines for Colorectal Adenomas Could Result in Reduced Burden on Endoscopy Services
Authors: AC Chircop, S Chetcuti Zammit, J Gerada, A Brincat
Journal: Gut (2016)

<h3>Introduction</h3> International guidelines recommend repeating surveillance colonoscopy in patients with colonic adenomas. We aimed to study local adherence to such guidelines. <h3>Methods</h3> Patients diagnosed with colonic adenomas between March and August 2008 were enrolled. Surveillance colonoscopy following adenoma removal was audited against the British Society of Gastroenterology guidelines: repeat in 5 years or no follow-up in low risk patients, repeat in 3 years in intermediate risk patients and repeat in 1 year in high risk patients. <h3>Results</h3> 165 patients (61.8% males; mean age 62.1) were risk stratified as per guidelines. 95 patients (57.6%) were low risk, 61 (37%) intermediate risk, and 9 (5.4%) high risk. In the low risk group, 43 patients (45%) had surveillance either ≥5 years or never and 52 (55%) had a shorter follow up. In the intermediate risk group, 9 (14.8%) patients had surveillance at 3 years, 28 (45.9%) patients before 3 years, 8 (13.1%) patients after 3 years and 16 (26.2%) patients had no follow up colonoscopy. In the high risk group, 5 (55.6%) patients had surveillance at 1 year, 1 (11.1%) patient before 1 year, 2 (22.2%) patients after 1 year and 1 (11.1%) patient had no follow up colonoscopy. 2 patients (1.2%) were diagnosed with interval colon cancer in the same year as the index colonoscopy. <h3>Conclusion</h3> Guideline non-adherence was noted in 65.5%, mainly due to too aggressive surveillance (49.1% early colonoscopies), increasing burden on endoscopy services. Late colonoscopies (6.1%) or no follow up colonoscopies (10.3%) were not the cause for interval cancers. <h3>Disclosure of Interest</h3> None Declared
Comparison Of Single Nucleotide Mutations (SNVs) and Copy Number Variants (CNVs) Detection In Formalin Fixed Paraffin Embedded (FFPE) and Paired Frozen Tumor Tissues Using Target Capture and Sequencing Approach
Authors: Yan W Asmann, Vivekananda Sarangi, Bruce W. Eckloff, Julie M Cunningham, Samantha J McDonough, Yeon K Lee, Eric D Wieben, Ahmet Dogan, Andrew L. Feldman, Susan L Slager, James R Cerhan, Anne J. Novak
Journal: Blood (2013)
Development of a Limiting Dilution Assay and MHC-Matched Transplantation Model to Detect Hematopoietic Stem Cell Activity in Zebrafish
Authors: Jill L. O. de Jong, Caroline E. Burns, Aye Tinmaung, Emily Pugach, Elizabeth Mayhall, Alexandra C.H. Smith, Henry A. Feldman, Yi Zhou, Leonard I. Zon
Journal: Blood (2008)
AB0514 Association of Anti-RO (SSA) Specificity with Clinical Manifestations in A spanish Population: Table 1
Authors: T. Rodriguez, P. Cossio, S. Rojas, V. Moreno, R. Veroz, M. Leόn, J.J. Aznar, M. Espárrago, E. Chamizo
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The Ro/La system is considered as an heterogeneous antigenic complex, constituted by three different proteins (52 kDa Ro, 60 kDa Ro and La) and four small RNAs particles. Anti-Ro are the most prevalent specificity among many autoimmune diseases. There is controversy regarding the relation between the different subunits of Ro antibody and the appearance of certain clinical aspects both in patients with autoimmune diseases and in healthy people<sup>1</sup>. <h3>Objectives</h3> To analyse antiRo Ab subtypes of people with or without autoimmune diseases criteria and determine whether there is a relation with any type of involvement. <h3>Methods</h3> We reviewed patients medical records who had more than one positive determination of anti-Ro, between 2010 and 2012 in the hospital of Merida, Spain. We collected data to support the existence of xerophthalmia and xerostomia, mucosal ulcers, Raynaud9s phenomenon, arthritis, interstitial lung disease (ILD), serositis, neurological involvement (polyneuropathy, mononeuritis multiplex and central involvement), nephritis and cutaneous lesions (SCLE, DLE, photosensitivity, malar rash and alopecia). We use Xi2 and, when necessary, Yates correction, to determine if there exist significative relation between the described pathologies and antibodies to 52 kDa Ro, 60 kDa Ro and La. <h3>Results</h3> Data of the relation of each pathology with the anti Ro subunits are represented in Table 1. From the 131 patients, the frequency of antibodies was found: 11 anti-Ro52 Ab, 33 antiRo 60 Ab, 73 antiRo52/60 Ab, 14 patients with unknown pattern and 47 also had associated anti-La Ab. We found statistically significant in the following cases: Xerophthalmia and xerostomía with anti-La (p&lt;0.01), mucosal ulcers with anti-La (p&lt;0.05), ILD with antiRO52 (p&lt;0.05), neuropathy anti-Ro52/60 (p&lt;0.01) and antiLa (p&lt;0.05); skin lesions with the abscence of anti-Ro52 (p&lt;0.01) and the presence of anti-La (p&lt;0.01). Of the 10 cases of ILD, three of them progressed to pulmonary fibrosis, all of them with antiRo 52, therefore with a relation statistically significant (p&lt;0.01). <h3>Conclusions</h3> We found that the anti-La Ab, was associated with sicca symptoms, mucosal ulcers, neuropathy and skin lesions. Ro52 subunit had a positive association with the occurrence of ILD and its progresion to fibrosis and negative association with skin lesions. Anti-Ro60 positivity was unrelated to any involvement. AntiRo52/60 positivity were associated with the onset of neurological symptoms. Studies bigger and with a larger sample of patients to confirm these results are needed. <h3>References</h3> Franceschini, F., &amp; Cavazzana, I. Autoimmunity, 38(1), 55–63. <h3>Disclosure of Interest</h3> None declared
AB0500 A Novel DNA-Peptide Complex Detects Anti-DSDNA Antibodies in SLE Sera
Authors: P. Migliorini, F. Panza, M.C. Alcaro, F. Petrelli, F. Angelotti, F. Pratesi, P. Rovero
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The detection of anti-dsDNA antibodies is critical for the diagnosis and follow-up of SLE patients. The presently available assays are characterized by a non-optimal specificity (solid phase assays) or sensitivity (CLIF test). <h3>Objectives</h3> To overcome the limits of CLIFT and solid phase chromatin assays, we explored the diagnostic potential of an assay based on plasmid DNA containing a highly bent fragment of 211 bp from <i>Crithidia Luciliae</i> microcircles, complexed with histone peptides. <h3>Methods</h3> Electrically neutral complexes of PK201/CAT plasmid (PK) DNA and histone (H) 4 peptides were evaluated by electromobility shift assay. Complexes of H4 peptides and PK were absorbed to the solid phase to detect IgG antibodies in sera. Sera from 109 SLE patients, 100 normals and 69 disease controls (systemic sclerosis, Sjogren9s syndrome, unclassified connective tissue disease) were tested. <h3>Results</h3> H4 (14–34) containing the consensus sequence for DNA binding interacts with PK retarding its migration. H4 (14–34)-PK complexes were used to test sera by ELISA; inhibition assays show that sera react with epitopes present on DNA or on the complex, not on the peptide. Anti-H4-PK antibodies were detected in 56% SLE sera (more frequently in patients with skin or joint involvement) vs 12% disease controls; antibody titer is correlated with ECLAM score and anti-C1q antibodies, negatively with C3 levels. Anti-H4-PK antibodies compared with CLIFT and solid phase dsDNA assays display moderate concordance. <h3>Conclusions</h3> The H4-PK assay is a simple and reliable test, endowed with high specificity and sensitivity, useful for the differential diagnosis and evaluation of disease activity of SLE patients. This assay increases the variety of anti-DNA antibodies that can be measured, complementing the assays currently used for the detection of anti-DNA antibodies. <h3>Disclosure of Interest</h3> None declared
Efficacy, Safety and Tolerability of a Novel High-Purity, Double Virus-Inactivated VWF/FVIII-Concentrate in the Treatment of Von Willebrand Disease (VWD) - Clinical Experience in the Treatment of Bleeding and Surgery.
Authors: B.A. Schwartz, J. Windyga, M. von Depka, O. Walter, M. Jansen, G. Auerswald
Journal: Blood (2007)
Toxicity and Risk Factors Contributing to Delayed Methotrexate (MTX) Elimination in Adult/Elderly Patients (pts) Treated with High-Dose Methotrexate Therapy (HDMTX), a 2-Year, Single Center Survey.
Authors: Stefan Schwartz, Peter Martus, Wolf-Dieter Ludwig, Renate Arnold, Markus Ruhnke, Agnieszka Korfel, David Kopitzke, Tim Auton, Eckhard Thiel
Journal: Blood (2006)
Bortezomib, Lenalidomide, and Dexamethasone (VRD) Consolidation and Lenalidomide Maintenance in Frontline Multiple Myeloma Patients: Updated Results of the IFM 2008 Phase II VRD Intensive Program
Authors: Murielle Roussel, Nelly Robillard, Philippe Moreau, Lotfi Benboubker, Cyrille Hulin, Gerald Marit, Xavier Leleu, Brigitte Pegourie, Christophe Fruchart, Denis Caillot, Anne-Marie Stoppa, Thierry Facon, Soraya Wuilleme, Hervé Avet-Loiseau, Michel Attal
Journal: Blood (2011)
Find yourself with a smile
Authors: G. De Agostini, L. Bonetti, C. Moleri, L. Belotti, S. Colombo, M. Pagani, M. Cabiddu, K. Borgonovo, L. Ruggeri, F. Rossi, A. Coinu, M.E. Cavalleri, A. Astori, M. Ghilardi, A. Aceti, M.A. Peccati, F. Petrelli, M. Losi, S. Barni
Journal: Annals of Oncology (2015)
Circulating Procoagulant Microparticles with Coagulation Factors IXa and XIa Cooperatively Induce Spontaneous Clotting in Plasmas of Patients with Hematological Disorders
Authors: Elena N. Lipets, Olga Vlasova, Evdokiya Urnova, Oleg Margolin, Anna Soloveva, Fazoil I Ataullakhanov, Mikhail A. Panteleev
Journal: Blood (2012)
New Cases of Acute Promyelocytic Leukemia Treatment by Arsenic Trioxide Alone and Their Long Term Follow up
Authors: Ardeshir Ghavamzadeh, Kamran Alimoghaddam, Shahrbano Rostami, Seyed Hamidolah Ghaffari, Mohamad Jahani, Mahdi Jalili, Seyed Asadollah Mousavi, Masood Iravani, Eisa Baybordi, Babak Bahar, Nassrin Alizadeh
Journal: Blood (2010)
Histone Deacetylase Inhibitor Promotes Rituximab-Induced Apoptosis in Non-Hodgkin’s B-Lymphoma Cells by NF-kB-Mediated Bcl-2/Bcl-XL Downregulation and c-Myc Degradation.
Authors: Weili Zhao, Lan Wang, Yuanhua Liu, Jinsong Yan, Christophe Leboeuf, Anne Janin, Zhu Chen, Saijuan Chen
Journal: Blood (2006)
P0083 : Sodium benzoate and rifaximin are able to restore blood-brain barrier integrity in cirrhotic rats with hepatic encephalopathy
Authors: S. Mouri, H. El Mourabit, C. Rey, R. Morichon, D. Wendum, E. Lasnier, C. Housset, N. Weiss, D. Thabut
Journal: Journal of Hepatology (2015)
Medicare’s Shift to Mandatory Alternative Payment Models
Authors: Hari Nathan, Justin B. Dimick
Journal: JAMA Surgery (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Re: Ernesto R. Cordeiro Feijoo, Arjun Sivaraman, Eric Barret, et al. Focal High-intensity Focused Ultrasound Targeted Hemiablation for Unilateral Prostate Cancer: A Prospective Evaluation of Oncologic and Functional Outcomes. Eur Urol 2016;69:214–20
Authors: Runqiang Yuan, Hongxing Huang
Journal: European Urology (2016)
Analysis with the LightCycler System® Identifies a Highly Significant Correlation between ZAP-70 mRNA Expression and Immunoglobulin Variable Heavy Chain Gene Mutational Status in Chronic Lymphocytic Leukemia.
Authors: Frank Dicker, Christine Ebenbichler, Karin Mann, Annemarie Linder, Susanne Schnittger, Claudia Schoch, Wolfgang Kern, Wolfgang Hiddemann, Torsten Haferlach, Sabine Lohmann
Journal: Blood (2005)
Treatment of Osteopenia/Osteoporosis after Allogeneic Hematological Cell Transplantation with Zoledronic Acid.
Authors: Wolfgang Hill, Johanna Ullmann, Andrea Baur, Georg Ledderose, Johanna Tischer, Dieter Muehlbayer, Andreas Hausmann, Michael Schmidt, Ulrike Haus, Hans-Jochem Kolb
Journal: Blood (2006)
Outcome of Patients 65 Years and Older with Myelodysplastic Syndrome (MDS) Receiving Allogeneic Hematopoietic Stem Cell Transplantation Compared to Patients 55-64 Years of Age
Authors: Ehab Atallah, Mary M. Horowitz, Brent Logan, Min Chen, Michael J. Boo, Corey S Cutler, Joachim Deeg, James L. Gajewski, Dennis L. Confer, Stephanie Farnia, Peter Greenberg, Erica Warlick, Daniel Weisdorf, J. Douglas Rizzo
Journal: Blood (2015)
Interleukin-1 α Genotype and Outcome of Unrelated Donor BMT for CML.
Authors: Parinda A. Mehta, Mary Eapen, Sharavi Gandham, James Elliott, Michelle Combs, Tiffany Wilke, Richard Aplenc, Margaret L. MacMillan, Daniel J. Weisdorf, Effie W. Petersdorf, John Klein, Stella M. Davies
Journal: Blood (2005)
Sarcopenia in patients (pts) with hepatocelluar carcinoma (HCC).
Authors: J. Meza-Junco, A. Montano-Loza, C. M. M. Prado, J. R. Lieffers, V. E. Baracos, V. Bain, J. L. Spratlin, M. B. Sawyer
Journal: Journal of Clinical Oncology (2011)

e14570 Background: Sarcopenia is defined as muscle mass < 2 standard deviations below sex-specific means of healthy young adults. It is associated with advanced malignancy, but not well studied in pts with different types and stages of cancer or different treatments. We aimed to establish sarcopenia frequency and determine if it predicts mortality in a cohort of cirrhotic HCC pts. Methods: Cirrhotic HCC pts who were consecutively evaluated for liver transplant and had a CT scan at the 3rd lumbar vertebrae were selected. Data were recovered from medical charts and skeletal muscle cross-sectional area was measured by CT. Sarcopenia was defined using previously published sex-specific cut-offs (Prado et al). Results: Fifty-one pts (M: 40, F: 11), with mean age of 57±6 years (range, 42-69) were followed for a median 14 months (range, 2-66 mths). Twenty-four (47%) pts died, 7 (14%) had liver transplant, and 20 (39%) remain alive. Cirrhosis etiology was hepatitis C (67%), alcohol (14%), hepatitis B (14%), and others (5%). Sarcopenia was present in 15 (29%) of pts. Twenty-nine (57%) pts received treatment with transarterial chemo/radioembolization (TACE/TARE), 12 (24%) ablation (radiofrequency/alcohol), 5 (10%) had combined treatment (TACE + ablation), and 5 (10%) received best supportive care. By univariate Cox analysis presence of encephalopathy (HR 10.59; 95% CI 2.08-53.84, P=0.004), INR (HR 6.90; 95% CI 1.26-37.70, P=0.03), Model for End-Stage Liver Disease (MELD) score (HR 1.17; 95% CI 1.05-1.30, P=0.004), Child-Pugh status (HR 2.77; 95% CI 1.41-5.42, P=0.003), tumor size (HR 1.82; 95% CI 1.02-3.25, P=0.04), TNM stage (HR 1.84; 95% CI 1.11-3.07, P=0.02), treatment type (HR 0.57; 95% CI 0.34-0.96, P=0.04), and sarcopenia (HR 2.84; 95% CI 1.26-6.39, P=0.01) were associated with increased risk of mortality. By multivariate Cox regression analysis, only TNM (HR 1.79, 95% CI 1.03-3.10, P=0.04), and sarcopenia (HR 2.42, 95% CI 1.01-5.80, P=0.048) were independently associated with early mortality. Median survival for sarcopenic pts was 16±7 vs. to 29±4 mths in non-sarcopenic (P=0.008). Conclusions: Sarcopenia is present in almost 1/3 of cirrhotic HCC pts and constitutes a strong and independent risk factor for mortality.
The Leukemogenic Potential of Cdx2 Is Dependent on Its N-Terminal Serine Sites and Can Be Counteracted by MAPK Inhibitors
Authors: Vijay P.S. Rawat, Vegi M. Naidu, Deepak Bararia, Silvia Thoene, Farid Ahmed, Leticia Quintanilla-Martinez, Wolfgang Hiddemann, Stefan Bohlander, Michaela Feuring-Buske, Christian Buske
Journal: Blood (2008)
High Prognostic Impact of Mixed Chimerism of Blood and Marrow In the First Year After Allogeneic Hematopoietic Stem Cell Transplantation: The Need to Rapidly Establish Complete Donor Chimerism.
Authors: Ellen Meijer, Lucia Duinhouwer, Eric Braakman, Joke Boonstra, Inge de Greef, Jeanette Doorduijn, Mojca Lavrencic, Bob Lowenberg, Jan Cornelissen
Journal: Blood (2010)